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HeartHuman mutations in PRKAG2, the gene encoding the γ2 subunit of AMP activated protein kinase (AMPK),
cause a glycogen storage cardiomyopathy. In a transgenic mouse with cardiac speciﬁc expression of the
Thr400Asn mutation in PRKAG2 (TGT400N), we previously reported initial cardiac hypertrophy (ages 2–
8 weeks) followed by dilation and failure (ages 12–20 weeks). We sought to elucidate the molecular
mechanisms of cardiac hypertrophy. TGT400N mice showed signiﬁcantly increased cardiac mass/body mass
ratios up to ∼3-fold beginning at age 2 weeks. Cardiac expression of ANP and BNP were ∼2- and ∼5-fold
higher, respectively, in TGT400N relative to wildtype (WT) mice at age 2 weeks. NF-κB activity and nuclear
translocation of the p50 subunit were increased ∼2- to 3-fold in TGT400N hearts relative to WT during the
hypertrophic phase. Phosphorylated Akt and p70S6K were elevated ∼2-fold as early as age 2 weeks. To
ascertain whether these changes in TGT400N mice were a consequence of increased AMPK activity, we
crossbred TGT400N with TGα2DN mice, which express a dominant negative, kinase dead mutant of the AMPK
α2 catalytic subunit and have low myocardial AMPK activity. Genetic reversal of AMPK overactivity led to a
reduction in hypertrophy, nuclear translocation of NF-κB, phosphorylated Akt, and p70S6K. We conclude
that inappropriate activation of AMPK secondary to the T400N PRKAG2 mutation is associated with the early
activation of NF-κB and Akt signaling pathway, which mediates cardiac hypertrophy.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Mutations in the gene PRKAG2, encoding the γ2 subunit of the
adenosinemonophosphate-activated protein kinase (AMPK), cause an
unusual glycogen storage cardiomyopathy in humans, characterized
by cardiac glycogen overload, ventricular preexcitation (Wolff–
Parkinson–White syndrome) and cardiac hypertrophy [1–3]. This
recently recognized cardiomyopathy is oftenmisdiagnosed as classical
hypertrophic cardiomyopathy (HCM), which is caused by sarcomere
protein mutations [4]. Cardiac hypertrophy occurs in up to 80% of
individuals with PRKAG2 mutations [5] and is usually progressive,
evolving to left ventricular dysfunction and dilatation [3,6]. Histopa-
thology shows an absence of myoﬁber disarray and less ﬁbrosis than is
usually found in HCM [7], suggesting that the signaling pathways and
molecular mechanisms underlying progression of cardiomyopathy
secondary to PRKAG2 mutations may be different from HCM. Our
recent genotype–phenotype studies in mice have characterized the
evolution of morphological changes of the left ventricle [4,8].niversity of Pittsburgh, 200
ttsburgh, PA 15213-2582, USA.
Institute of Chemical Technol-
ll rights reserved.In an earlier report [8], we constructed and characterized a
transgenic mouse overexpressing human PRKAG2with the previously
described [1] Thr400Asn (T400N) mutation (TGT400N). This mouse
recapitulates the human phenotype, developing left ventricular
hypertrophy at an early age which is maximal at age 8 weeks,
progressing to left ventricular dilation and impaired contractility by
age 12 weeks, and end-stage heart failure at age 20 weeks. The
massive cardiac hypertrophy seen in this cardiomyopathy secondary
to PRKAG2 mutations is not merely a reﬂection of excess glycogen.
Direct measurements of glycogen content suggest that glycogen is
responsible for only ∼4% of the increase in cardiac mass in TGT400N
mice. However, the molecular pathways that contribute to hypertro-
phy have not been previously studied.
One of the cardinal features of heart failure of many different
etiologies is left ventricular (LV) hypertrophy. Therapies that reduce
mortality in patients with heart failure invariably produce favorable
effects on the hypertrophy process and limit disease progression [9].
Therefore, understanding the molecular basis of hypertrophy in
glycogen storage cardiomyopathies may be essential in the develop-
ment of therapeutic strategies. The aims of this study were to
determine the early molecular signaling events that are associated
with cardiac hypertrophy, focusing on pathways known to be
modulated by AMPK.
In the present study, we demonstrate in the TGT400N murinemodel
of glycogen storage cardiomyopathy that inappropriate activation of
Table 1
Real-time quantitative PCR primers used to quantify mRNA expression.
Anp Sense 5′-GAAAAGCAAACTGAGGGCTCTG-3′
Antisense 5′-CCTACCCCCGAAGCAGCT-3′
Bnp Sense 5′-AGGCGAGACAAGGGAGAACA-3′
Antisense 5′-GGAGATCCATGCCGCAGA-3′
FasL Sense 5′-CATGGAGTGGTCCTTAATGC-3′
Antisense 5′-AAGTAGACCCACCCTGGAAG-3′
Ifng Sense 5′-GAAAAGGATGGTGACATGAA-3′
Antisense 5′TTGGCAATACTCATGAATGC-3′
Il6 Sense 5′-CAGAGGATACCACTCCCAACA-3′
Antisense 5′-CCAGTTTGGTAGCATCCATC-3′
Il10 Sense 5′-CAGAGCCACATGCTCCTAGA-3′
Antisense 5′-TGTCCAGCTGGTCCTTTGTT-3′
Nlrp12 Sense 5′-TGTAGGCTGCAGATGATCCA-3′
Antisense 5′-GAACAGAAGCCAGGGATCG-3′
Tlr2 Sense 5′-GGGGCTTCACTTCTCTGCTT-3′
Antisense 5′-AGCATCCTCTGAGATTTGACG-3′
Tlr9 Sense 5′-GAATCCTCCATCTCCCAACAT-3′
Antisense 5′-CCAGAGTCTCAGCCAGCACT-3′
Tnfsf14 Sense 5′-CGATCTCACCAGGCCAAC-3′
Antisense 5′-TCCACCAATACCTATCAAGCTG-3′
Zap70 Sense 5′-CAGACCGACGGCAAGTTC-3′
Antisense 5′-CCATAGACCAGGGACAGTGC-3′
Cyclophilin Sense 5′-TGTGCCAGGGTGGTGACTT-3′
Antisense 5′-TCAAATTTCTCTCCGTAGATGGACTT-3′
285S.K. Banerjee et al. / Biochimica et Biophysica Acta 1802 (2010) 284–291AMPK triggers hypertrophic signaling at a very early age with the
activation of the Akt signaling pathway and the transcription factor,
nuclear factor κB (NF-κB). Genetic reversal of AMPK overactivity leads
to a reduction in hypertrophy by reducing NF-κB nuclear transloca-
tion, phosphorylated Akt, and p70S6K.
2. Methods
2.1. Construction of TGT400N transgenic mice
The construction and initial characterization of the transgenic
mouse with the human T400N mutation in PRKAG2 (TGT400N) have
been previously described [8]. Cardiac-speciﬁc expression of the
transgene was achieved with the α-myosin heavy chain promoter.
Transgenic mice were produced in the FVB background and
maintained as heterozygotes by breeding with wildtype (WT)
FVB mice. FVB background TGα2DN mice, which express a dominant
negative, kinase dead mutant of the AMPK α2 catalytic subunit
and have low myocardial AMPK activity, have been previously
described [10]. Double transgenic mice (TGT400N/TGα2DN) were
obtained by crossbreeding. Mice aged 2–20 weeks were used for
the study. This investigation conforms with the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996) and
was approved by the University of Pittsburgh Institutional Animal
Care and Use Committee.
2.2. Analysis of protein expression
Extraction of nuclear and whole cell protein fractions, immuno-
blotting, autoradiography, and densitometry were performed as
described previously [11–13]. Protein levels were measured by the
Bradford method (Bio-Rad). An equal amount (50 μg) of protein was
separated by sodium dodecylsulfate polyacrylamide gel electropho-
resis (SDS-PAGE). After electrophoresis, protein was transferred to
PVDF membranes (Amersham Biosciences). The membranes were
then blocked in Tris-buffered saline Tween-20 (TBS-T; 10mM Tris, pH
7.5, 150 mM NaCl, 0.05% Tween-20) and 5% non-fat dry milk for 1 h,
and subsequently washed and incubated with primary antibodies in
TBS-T and 2% bovine serum albumin (BSA) at 4 °C overnight. The
following antibodies and titers were used: Akt (1:1000 dilution, Cell
Signaling, #9272), phospho-Ser473 Akt (1:1000 dilution, Cell Signal-
ing, #9271), phospho-Thr389 p70S6K (1:1000 dilution, Cell Signaling,
#9205), phospho-Thr180/Tyr182 p38 MAPK (1:1000 dilution, Cell
Signaling, #9211), phospho-Thr202/Tyr204 ERK1/2 (1:1000 dilution,
Cell Signaling, #9101), phospho-Tyr705 STAT3 (1:1000 dilution, Cell
Signaling, #9131), calcineurin A (1:500 dilution, Chemicon,
#AB1695), NF-κB p50 (1:200 dilution, Santa Cruz, #sc-114), and
NFATc3 (1:200 dilution, Santa Cruz, #sc-23814). After washing with
TBS-T, membraneswere incubatedwith anti-rabbit (1:10000 dilution,
Amersham, #NA934V) or anti-goat (1:2000 dilution, Santa Cruz, sc-
2020) horseradish peroxidase conjugated secondary antibody for 1 h.
Signal was detected by chemiluminescence using the ECL detection
system (Amersham). Gel staining with Coomassie Blue was used as an
internal control for equal loading of protein. Quantiﬁcation of bands
on X-ray ﬁlm was performed using Image J Software (NIH).
2.3. RNA isolation and real-time quantitative PCR (QPCR)
Total RNA was isolated from whole heart with TRIzol (Invitrogen).
Reverse transcriptase reactions were performed as described [11,13],
using the Superscript III First-Strand Kit (Invitrogen) for ﬁrst-strand
cDNA synthesis. Primers for real-time quantitative PCR (QPCR)
analysis were designed using published sequence information,
avoiding regions of homology with other genes, or were purchased
as prevalidated sequences from a commercial source (RealtimePrimers) (Table 1). For each gene, 10 ng of cDNA were analyzed on
an ABI PRISM 7700 using Absolute SYBR Green ROX PCR Master Mix
(Thermo Scientiﬁc). Fold-change analysis was based on normalizing
to cyclophilin transcript levels in each sample. As an initial screen of
expression of NF-κB related genes, a commercially available kit with
QPCR primer assays on a 96-well plate (Mouse NFκB Signaling
Pathway RT2 Proﬁler™ PCR Array, SABioscences) was interrogated
according to the manufacturer's instructions. This array proﬁles the
expression of 84 key genes related to NFκB-mediated signal
transduction. Differences in expression identiﬁed by this array were
validated by individual QPCR.
2.4. NF-κB binding activity
Electrophoretic mobility shift assays (EMSA) were performed as
described [12]. In brief, nuclear proteins were isolated and protein
concentrations were measured using BSA as a standard by the
Bradford method (Bio-Rad). Protein-DNA binding was carried out in a
ﬁnal volume of 20 μl. Four μl of a 5× binding buffer (1× concentration
of 5% glycerol, 1 mMMgCl2, 0.5 mM EDTA, 40mMKCl, 40 mM Tris, pH
8.0) along with 800 ng of dIdC and 20 μg nuclear proteins was added
to each tube. For speciﬁc and nonspeciﬁc competitor reactions, 100-
fold excess of the appropriate unlabelled double-strand DNA was
added: speciﬁc, AGTTGAGGGGACTTTCCCAGGC (NF-κB) and non-
speciﬁc, CGCTTGATGAGTCAGCCGGAA (AP1) (complementary strand
not shown; Promega). Two μl of 32P-labeled NF-κB probe (approxi-
mately 20,000 cpm/ng) was added to each reaction and incubated for
20 min at room temperature. Four μl of loading buffer (prepared with
0.85 ml 1× binding buffer and 0.15 g Ficoll 400 powder) was added to
each reaction, and samples were then placed on ice until loading.
Samples were resolved on a 4% (80:1 acrylamide:bis) acrylamide gel
in 0.25× TBE buffer. The gel was then exposed to a storage phosphor
cassette and analyzed with ImageQuant (Molecular Dynamics).
In addition, NF-κB binding to its consensus binding site was
measured using a commercially available colorimetric assay
(TransAM™ NFκB p50 DNA-binding ELISA kit, Active Motif) according
to the manufacturer's instructions.
2.5. Statistical analysis
Results are expressed as mean±SE. Differences between WT and
TGT400N mice at each age were compared by Student's t test, whereas
Fig. 1. The PRKAG2 T400Nmutation was associated with upregulation of the markers of
cardiac hypertrophy, (A) ANP and (B) BNP, in TGT400N myocardium as measured by
QPCR. n=3/group. Data are expressed as mean±SE. Open bars, WT; shaded bars,
TGT400N. ⁎pb0.05; ⁎⁎pb0.01 relative to WT.
286 S.K. Banerjee et al. / Biochimica et Biophysica Acta 1802 (2010) 284–291differences among WT, TGT400N, and TGT400N/TGα2DN mice were
analyzed by ANOVA followed by post hoc Bonferroni correction for
multiple comparisons. A p value of less than 0.05 was considered
signiﬁcant.
3. Results
3.1. The PRKAG2 T400N mutation causes cardiac hypertrophy
The PRKAG2 T400N mutation resulted in cardiac hypertrophy in
TGT400N mice as early as age 2 weeks, which was maximal at age
8 weeks. We previously showed a progressive increase in cardiac
mass/bodymass ratio in TGT400N mice relative toWT littermates from
age 1 week, through 2 weeks, to 4 weeks [8]. At age 8 weeks, the
cardiac mass/body mass ratio (mg/g) increased further in TGT400N
mice to 19.4±0.9, relative to 4.1±0.1 in WT mice (pb0.01, n=6/
group), consistent with progressive cardiac hypertrophy. To conﬁrm
that morphologically evident cardiac hypertrophy was associated
with induction of corresponding molecular markers of cardiac
hypertrophy, we quantiﬁed ANP and BNP by QPCR at an early age
(n=3/group). Cardiac hypertrophy in TGT400N mice was accompa-
nied by the upregulation of cardiac ANP and BNP transcripts. There
were signiﬁcant increases in ANP and BNP in TGT400N hearts at age
2 weeks (Fig. 1A and B).
Because TGT400N cardiac myocytes are laden with glycogen [8], we
determined the contribution of glycogen to the increased cardiacTable 2
Relative contribution of glycogen to cardiac hypertrophy in TGT400N mice.
4 Weeks
WT
Cardiac mass (mg) 66.7±2.0
Cardiac glycogen content (μg/mg cardiac mass) 0.31±0.05
Contribution of glycogen to increased cardiac mass (%)
n=5 / group.mass. In TGT400N mice, the average cardiac mass was increased 221±
14% and 352±51% relative to WT littermates at ages 4 weeks and
8 weeks, respectively (n=5/group). However, the contributions of
glycogen to increased cardiac mass at ages 4 weeks and 8 weeks were
only 4.4% and 3.5%, respectively (Table 2). Therefore, most of the
increased cardiacmass observed in TGT400Nmice appears not to be the
direct result of glycogen accumulation, prompting us to examine
signaling pathways regulated by AMPK and known to be associated
with cardiac remodeling.
3.2. Early activation of the NF-κB and Akt signaling pathways contribute
to cardiac hypertrophy in TGT400N mice
To determine which hypertrophic signaling pathways are associ-
ated with cardiac hypertrophy in TGT400N mice, we focused on those
pathways which are known or suspected to be direct or indirect
targets of AMPK. Speciﬁcally, AMPK has been shown to activate
nuclear factor κB (NF-κB) [14,15], p38 mitogen-activated protein
kinase (p38 MAPK) [16–20], and Akt [21–26].
NF-κB is a transcription factor which regulates genes mediating
inﬂammation and hypertrophy, and it is activated during oxidative
stress. NF-κB activity as measured by EMSA was upregulated in
TGT400N hearts from age 2 through 20 weeks (Fig. 2A). We conﬁrmed
elevation of NF-κB binding activity to its consensus binding site up to
2.7-fold in TGT400N hearts at ages 2, 8, and 20 weeks using a
commercially available colorimetric assay (Fig. 2B). Since NF-κB
activation involves the nuclear translocation of its subunits, we
assessed the expression of the p50 subunit in nuclear protein extracts
from TGT400N and WT hearts by immunoblot. Elevated levels of p50
were observed in the nucleus in TGT400N mice at ages 2 and 8 weeks
(Fig. 2C).
To screen for changes in mRNA expression of a wide range genes
related to NF-κB mediated signal transduction, we performed QPCR
using the Mouse NFκB Signaling Pathway RT2 Proﬁler™ PCR Array
(SABioscences) that quantiﬁes 84 genes. Genes showing upregulation
of at least 2-fold in TGT400N relative to WT hearts on the array were
further validated with individual QPCR in TGT400N and WT hearts at
ages 2 and 8 weeks (n=3/group) (Table 3). Fas ligand (FasL) was
upregulated at ages 2 and 8 weeks, whereas toll-like receptor 2 (Tlr2)
and tumor necrosis factor (ligand) superfamily, member 14 (Tnfsf14)
were upregulated only at age 8 weeks. All three genes are known to
activate NF-κB and have been associated with cardiac remodeling
[27–29]. Furthermore, interleukin 6 (Il6), upregulated at age 8 weeks,
is an NF-κB responsive gene that is known to mediate cardiac
hypertrophy [30,31]. Interleukin 10 (Il10), upregulated at ages 2 and
8 weeks, is also involved in the NF-κB signal transduction pathway
and has been shown to be associated with cardiac hypertrophy [32].
The ﬁnding that toll-like receptor 9 (Tlr9) is upregulated at age
8 weeks is intriguing because it impairs cardiac contractility [33], and
TGT400N hearts develop progressive dysfunction beyond age 8 weeks
[8]. In contrast, interferon gamma (Ifng), upregulated at 2 and
8 weeks, is known to inhibit cardiac hypertrophy [34], and may
represent a compensatory effect in response to pathological hyper-
trophy in TGT400N hearts.
We next examined whether increased NF-κB activity in TGT400N
hearts was associated with activation of hypertrophic signaling8 Weeks
TGT400N WT TGT400N
214.5±9.6 98.8±8.3 446.5±51.1
31.10±4.1 0.30±0.05 28.02±2.64
4.4±0.6% 3.5±0.3%
Fig. 2.Nuclear factor κB (NF-κB) was activated in TGT400N mice. (A) NF-κB activity as measured by EMSA was higher in TGT400N hearts at all ages analyzed (2–20 weeks). Hearts from
transgenic mice overexpressing TNFα (TGTNFα) were used as a positive control. (B) NF-κB binding to its consensus binding site was measured using a commercially available
colorimetric assay, which conﬁrmed elevation of binding activity in TGT400N hearts at ages 2, 8, and 20 weeks. Data are expressed as mean±SE. Open bars, WT; shaded bars, TGT400N.
⁎, pb0.05; ⁎⁎, pb0.01; ⁎⁎⁎, pb0.001 relative to WT. n=3-8/group. (C) The p50subunit of NF-κB was elevated in nuclear protein extracts from TGT400N hearts relative to WT
littermates at ages 2 and 8 weeks as measured by immunoblot. Coomassie blue staining was used to document the relative quantity of protein loaded.
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upregulates protein synthesis, was activated. We quantiﬁed the
active, phosphorylated forms of Akt and another downstream
signaling protein, p70S6K, by immunoblot. There were signiﬁcant
increases in phosphorylated Akt and p70S6K in TGT400N relative toWT
hearts at ages 2 and 8 weeks (n=3/group) (Fig. 3). No difference in
total Akt levels was observed.
3.3. The calcineurin and MAPK pathways do not contribute to cardiac
hypertrophy in TGT400N mice
We systematically analyzed other known mediators of cardiac
hypertrophy [35,36]. To assess whether activation of the calcineurin-
NFAT signaling pathway is associated with hypertrophy in TGT400N
hearts, we quantiﬁed calcineurin A by immunoblot (n=3/group).
There were no increases in calcineurin A levels and cytoplasmic
NFATc3 levels in TGT400N hearts at ages 2 and 8 weeks (Fig. 4). Instead,
a signiﬁcant decrease in calcineurin A was observed in TGT400N hearts
at age 8 weeks, suggesting that activation of calcineurin-NFAT
signaling pathway was not responsible for early cardiac hypertrophy
in TGT400N mice.
We also examined whether increased MAPK activity was associ-
ated with hypertrophy in TGT400N hearts. We quantiﬁed the active,
phosphorylated forms of p38 MAPK and ERK1/2, and anotherdownstream signaling protein, phosphorylated STAT3, by immuno-
blot (n=3/group). There was no increase in levels of phosphorylated
p38 MAPK (Fig. 5A and B), phosphorylated ERK1/2 (Fig. 5C and D),
and phosphorylated STAT3 levels (Fig. 5E) at ages 2 and 8 weeks.
These data suggest the absence of a role for MAPK signaling pathway
in cardiac hypertrophy in TGT400N mice.
3.4. Normalization of AMPK activity leads to normalization of NF-κB
levels in the nucleus, normalization of Akt and p70S6K signaling,
and attenuation of cardiac hypertrophy in TGT400N mice
To ascertain whether attenuation of inappropriate AMPK activity
in TGT400N hearts would lead to attenuation of the associated
upregulation in NF-κB, Akt, and p70S6K signaling that we observed,
we crossbred TGT400N mice with TGα2DN mice, which express a
dominant negative, kinase dead mutant of the AMPK α2 catalytic
subunit and have low myocardial AMPK activity [10]. Thr172
phosphorylation of the α subunit of AMPK, which reﬂects AMPK
activity, was assessed by immunoblotting and was found to be
reduced in TGT400N/TGα2DN hearts relative to TGT400N hearts (22±5
versus 100±22 in arbitrary units, n=3/group, pb0.05). As we have
previously reported [8], TGT400N/TGα2DN mice exhibited an attenua-
tion in cardiac hypertrophy as measured by cardiac mass/body mass
ratios and by echocardiography. Speciﬁcally, at age 2 weeks, cardiac
Table 3
Upregulation of genes related to NF-κB mediated signal transduction in TGT400N hearts.
Gene name Gene symbol Cardiac expression (arbitrary units)
Age (weeks)
2 8
TGT400N WT p TGT400N WT p
Fas ligand (TNF superfamily, member 6) FasL 1.31±0.01 1.00±0.01 b0.001 2.22±0.01 1.00±0.01 b0.01
Interferon gamma Ifng 2.53±0.06 1.00±0.01 b0.01 2.38±0.02 1.00±0.04 b0.05
Interleukin 6 Il6 0.28±0.01 1.00±0.06 b0.05 4.68±0.15 1.00±0.03 b0.01
Interleukin 10 Il10 2.21±0.05 1.00±0.02 b0.05 4.93±0.02 1.00±0.04 b0.01
NLR family, pyrin domain containing 12 Nlrp12 1.07±0.01 1.00±0.01 b0.01 1.21±0.02 1.00±0.00 NS
Toll-like receptor 2 Tlr2 1.02±0.01 1.00±0.01 NS 4.45±0.01 1.00±0.01 b0.001
Toll-like receptor 9 Tlr9 0.69±0.01 1.00±0.02 b0.05 1.96±0.04 1.00±0.00 b0.01
Tumor necrosis factor (ligand) superfamily, member 14 Tnfsf14 0.67±0.01 1.00±0.01 b0.05 1.82±0.02 1.00±0.01 b0.01
Zeta-chain (TCR) associated protein kinase Zap70 1.60±0.02 1.00±0.02 b0.01 1.49±0.01 1.00±0.01 b0.01
NS, not signiﬁcant.
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TGα2DN were 4.9±0.2, 7.4±0.2, and 6.1±0.2 respectively (n=3/
group, pb0.001 for TGT400N versus WT, and pb0.01 for TGT400N/
TGα2DN versus TGT400N). Corresponding to these changes, signiﬁcantly
reduced levels of the p50 subunit of NF-κB in the nucleus were
observed in TGT400N/TGα2DN hearts relative to TGT400N hearts at age
2 weeks (n=3/group) (Fig. 6A and B). Similarly, phosphorylated Akt
and p70S6K were signiﬁcantly decreased in TGT400N/TGα2DN hearts
relative to TGT400N hearts at age 2 weeks (n=3/group) (Fig. 6C–E).
These data conﬁrm that attenuation of inappropriate AMPK activity in
TGT400N hearts leads to an attenuation of increased NF-κB, Akt, and
p70S6K signaling associated with cardiac hypertrophy.
4. Discussion
PRKAG2 mutations in humans cause cardiac hypertrophy and
sudden cardiac death [1–3]. Previously, in a transgenic mouse model
with cardiac speciﬁc expression of the T400N mutation in PRKAG2
(TGT400N), we have shown that the mutation leads to early
inappropriate activation of cardiac AMPK and glycogen deposition
[8]. Concurrently, the heart manifests cellular and ventricular wall
hypertrophy, only a small proportion of which is attributable toFig. 3. Activation of the Akt signaling pathway was associated with cardiac hypertrophy in T
increased levels of phosphorylated Akt and phosphorylated p70S6K in TGT400N hearts relativ
Coomassie blue staining was used to document the relative quantity of protein loaded for
loading, indicated 3-fold and 2-fold increases in phosphorylated Akt levels in TGT400N hearts
immunoblots, corrected for protein loading, indicated 2-fold increases in phosphorylated p
expressed as mean±SE. Open bars, WT; shaded bars, TGT400N. ⁎pb0.05; ⁎⁎pb0.01.glycogen deposition. The speciﬁc mechanisms whereby PRKAG2
mutations activate hypertrophic signaling pathways and result in
cardiac dilation and failure are unknown. In this study, we analyzed
the TGT400N model to dissect the downstream effects of this mutation
on signaling pathways mediating cardiac hypertrophy. We demon-
strated early changes in hypertrophic signaling pathways that are
targets of AMPK, including Akt and the transcription factor NF-κB.
We analyzed known or suspected AMPK targets that could
potentially activate hypertrophic pathways, including the transcrip-
tion factor NF-κB [14,15], p38 mitogen-activated protein kinase (p38
MAPK) [16–20], and Akt [21–26]. Additionally, we systematically
analyzed other pathways known to mediate cardiac hypertrophy and
which may be active in TGT400N hearts. Our analysis showed that NF-
κB was activated in TGT400N hearts. NF-κB is a redox-sensitive
transcription factor that can be activated during oxidative stress
[37]. Interestingly, elevated intracellular glucose stimulates the
translocation of NF-κB [35]. Increased cardiac glucose uptake has
been documented in both the TGT400N model (Banerjee and Ahmad,
unpublished data), and in a transgenic mouse model with the N488I
mutation [36]. Therefore, NF-κB may be activated not only by direct
AMPK effects but also by indirect effects of perturbations in
intracellular glucose. We also observed early activation of the Akt-GT400N mice. (A) A representative immunoblot of total cardiac protein extracts showed
e to WT at ages 2 and 8 weeks. There was no difference in total Akt level at either age.
immunoblot. (B) Densitometry analysis of several immunoblots, corrected for protein
relative to WT at ages 2 and 8 weeks, respectively. (C) Densitometry analysis of several
70S6K in TGT400N hearts relative to WT at ages 2 and 8 weeks. n=3/group. Data are
Fig. 4. The calcineurin signaling pathway was not activated in TGT400N mice. (A) A
representative immunoblot of total cardiac protein extracts showed no difference in
levels of calcineurin A in TGT400N hearts relative to WT littermates at age 2 weeks, but
mildly decreased levels at age 8 weeks. Coomassie blue staining was used to document
the relative quantity of protein loaded for the immunoblot. (B) Densitometry analysis of
several immunoblots, corrected for protein loading, indicated a signiﬁcant decrease in
calcineurin A levels in TGT400N hearts relative to WT only at age 8 weeks. n=3/group.
Data are expressed as mean±SE. Open bars, WT; shaded bars, TGT400N. ⁎pb0.05. (C) A
representative immunoblot of cytoplasmic cardiac protein extracts showed no change
in NFATc3 levels in TGT400N hearts relative toWT at ages 2 and 8 weeks. Coomassie blue
staining was used to document the relative quantity of protein loaded for the
immunoblot.
289S.K. Banerjee et al. / Biochimica et Biophysica Acta 1802 (2010) 284–291mTOR signaling pathway. Increased levels of phosphorylated Akt and
another downstream mediator, phosphorylated p70S6K, were pres-
ent. However, we found no activation of the calcineurin and MAPK
(phosphorylated ERK, phosphorylated p38MAPK and phosphorylated
STAT3) pathways in TGT400Nmice. Our results suggest that both NF-κBFig. 5. The MAPK signaling pathway was not activated in TGT400N mice. (A) A
representative immunoblot of total cardiac protein extracts showed no change in
phosphorylated p38 MAPK in TGT400N hearts relative to WT at ages 2 and 8 weeks.
Coomassie blue staining was used to document the relative quantity of protein loaded
for the immunoblot. (B) Densitometry analysis of several immunoblots, corrected for
protein loading, indicated no difference in phosphorylated p38 MAPK levels at ages 2
and 8 weeks. n=3/group. Data are expressed as mean±SE. Open bars, WT; shaded
bars, TGT400N. (C) An immunoblot of total cardiac protein extracts showed no increased
levels of phosphorylated ERK1/2 in TGT400N hearts relative toWT at ages 2 and 8weeks.
Coomassie blue staining was used to document the relative quantity of protein loaded
for the immunoblot. (D) Densitometry analysis of several immunoblots, corrected for
protein loading, indicated no increase in phosphorylated ERK1/2 levels in TGT400N hearts
relative to WT at ages 2 and 8 weeks. n=3/group. Data are expressed as mean±SE.
Open bars, WT; shaded bars, TGT400N. (E) An immunoblot of total cardiac protein
extracts showed no change in phosphorylated STAT3 levels in TGT400N hearts relative to
WT at ages 2 and 8 weeks.activation and Akt-mTOR signaling pathway participate in the
development of cardiac hypertrophy in the TGT400N mouse.
We speculated that initial inappropriate activation of AMPK,
secondary to the T400N mutation in PRKAG2, triggers a hypertrophic
remodeling program through its targets, NF-κB and Akt. Therefore, we
hypothesized that early reduction of AMPK activity in the TGT400N
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We constructed a double transgenic mouse (TGT400N/TGα2DN) by
crossbreeding TGT400N mice with TGα2DN mice, which express a
dominant negative, kinase dead mutant of the AMPK α2 catalytic
subunit and have low myocardial AMPK activity [10]. Consistent with
our hypothesis, TGT400N/TGα2DN mice exhibited attenuation of
hypertrophy and reductions in nuclear translocation of NF-κB and
expression of phosphorylated Akt and p70S6K. However, we have
previously shown that AMPK activity is biphasic in the TGT400N heart,
with early activation, followed by depression, and then recovery to
WT levels [8]. It is possible that that the initial enhanced AMPK
activity is required to establish the primary defect, but that with time
enhanced glucose uptake and glycogen deposition is a stimulus forcontinued NF-kB activation that subsequently drives cardiac hyper-
trophy and eventually dilation [38,39].
As detailed elsewhere [40–43], several studies in both in vitro
cardiac myocyte cultures and in vivo mouse models have suggested
that the NF-κB signaling pathway is an important intracellular
mediator of cardiac hypertrophy. NF-κB has been found to be
upregulated in pathological and physiological cardiac hypertrophy.
Furthermore, inhibition of NF-κB prevents hypertrophy in response to
many of these stimuli, such as phenylephrine, endothelin-1, angio-
tensin II, and chronic pressure overload. Whereas it is now well
established that intracellular calcium stimulates hypertrophy by
activation of calcineurin and NFAT, recent evidence suggests that
calcium can also alternatively activate NF-κB in a calpain-dependent
manner. The mechanisms by which NF-κB mediates cardiac hyper-
trophy have not been fully elucidated, but include activation of the
interleukin 6 (Il6) receptor gp130 [30,31] and transcriptional
activation of antiapoptotic genes. Of note, we found Il6 expression
to be increased in TGT400N hearts. Although the preponderance of
evidence now supports that NF-κB inhibition antagonizes cardiac
hypertrophy, it is important to note that there are caveats. NF-κB can
mediate both anti- and proapoptotic effects, so that NF-κB inhibition
may either protect the myocardium from or predispose it to apoptosis
depending on the nature of the stimulus. For example, some studies
have shown that NF-κB inhibition promotes apoptosis after TNF-α
treatment or hypoxia/reoxygenation, whereas other studies have
documented the opposite effects. Our data suggest that NF-κB is an
important mediator of cardiac hypertrophy, and possibly the
transition to dilation and heart failure, in PRKAG2 cardiomyopathy.
Further work will be required for complete elucidation of the
pathophysiology of PRKAG2 cardiomyopathy. For example, echocar-
diography shows early hypercontractility in TGT400N hearts that
progresses to normal contractility and eventually impaired contrac-
tility [8]. The acute and chronic effects of PRKAG2 mutations on
sarcomere function are unknown. Furthermore, although we have
observed increasing cardiac ﬁbrosis with age in TGT400N mice, the
molecular mechanisms promoting ﬁbrosis are currently under
investigation. Finally, the direct molecular electrophysiological effects
of PRKAG2mutations underlying rhythm and conduction disturbances
observed clinically in patients and in TGT400N mice require further
study [44].
We conclude that the T400N mutation in PRKAG2 initiates cardiac
hypertrophy at an early age, a process associated with activation of
the transcription factor, NF-κB, and the Akt-mTOR signaling pathway.
Identiﬁcation of cardiac hypertrophic pathways in the setting of a
PRKAG2mutation, at early stages in the evolution of disease, suggests
possible therapeutic targets, which remain to be tested in further
studies.Fig. 6. Normalization of AMPK activity normalized NF-κB, Akt, and p70S6K signaling in
TGT400N hearts at age 2 weeks. (A) A representative immunoblot of nuclear protein
extracts showed increased expression of the p50 subunit of NF-κB in TGT400N hearts
relative to WT, an effect which was attenuated in TGT400N/TGα2DN hearts. Coomassie
blue staining was used to document the relative quantity of protein loaded for the
immunoblot. (B) Densitometry analysis, corrected for protein loading, conﬁrmed
signiﬁcantly (pb0.01) increased nuclear p50 levels in TGT400N hearts relative to WT,
but signiﬁcantly (pb0.01) reduced levels in TGT400N/TGα2DN hearts relative to TGT400N.
(C) A representative immunoblot of total cardiac protein extracts showed increased
levels of phosphorylated Akt and phosphorylated p70S6K in TGT400N hearts relative to
WT, an effect which was attenuated in TGT400N/TGα2DN hearts. Coomassie blue
staining was used to document the relative quantity of protein loaded for the
immunoblot. (D) Densitometry analysis, corrected for protein loading, conﬁrmed
signiﬁcantly (pb0.05) increased phosphorylated Akt levels in TGT400N hearts relative to
WT, which were normalized in TGT400N/TGα2DN hearts (pb0.05). (E) Densitometry
analysis, corrected for protein loading, conﬁrmed signiﬁcantly (pb0.01) increased
phosphorylatedp70S6K levels in TGT400Nhearts relative toWT, but signiﬁcantly (pb0.05)
reduced levels in TGT400N/TGα2DN hearts relative to TGT400N. n=3/group. Data in bar
graphs are expressed as mean±SE. Open bars, WT; shaded bars, TGT400N; closed bars,
TGT400N/TGα2DN. ⁎pb0.05 and ⁎⁎pb0.01 versus WT; †pb0.05 and ††pb0.01 versus
TGT400N.
291S.K. Banerjee et al. / Biochimica et Biophysica Acta 1802 (2010) 284–291Acknowledgments
We thank Charles F. McTiernan, Ph.D., University of Pittsburgh, for
providing reagents, technical protocols, and advice; and Rong Tian, M.D.,
Ph.D., Brigham and Women's Hospital, for sharing TGα2DN mice. This
work was supported by an American Heart Association Scientist
Development Grant (FA), Postdoctoral Fellowships from the American
Heart Association and the Hillgrove Foundation (SKB), and the
Cardiovascular Institute of the University of Pittsburgh (Barry London,
Director) (FA). FA is aDoris DukeCharitable Foundation Clinical Scientist.
References
[1] M. Arad, D.W. Benson, A.R. Perez-Atayde, W.J. McKenna, E.A. Sparks, R.J. Kanter, K.
McGarry, J.G. Seidman, C.E. Seidman, Constitutively active AMP kinase mutations
cause glycogen storage disease mimicking hypertrophic cardiomyopathy, J. Clin.
Invest. 109 (2002) 357–362.
[2] M.H. Gollob, M.S. Green, A.S. Tang, T. Gollob, A. Karibe, A.S. Ali Hassan, F. Ahmad, R.
Lozado, G. Shah, L. Fananapazir, L.L. Bachinski, R. Roberts, Identiﬁcation of a gene
responsible for familial Wolff–Parkinson–White syndrome, N. Engl. J. Med. 344
(2001) 1823–1831.
[3] E. Blair, C. Redwood, H. Ashraﬁan, M. Oliveira, J. Broxholme, B. Kerr, A. Salmon, I.
Ostman-Smith, H. Watkins, Mutations in the gamma(2) subunit of AMP-activated
protein kinase cause familial hypertrophic cardiomyopathy: evidence for the
central role of energy compromise in disease pathogenesis, Hum. Mol. Genet. 10
(2001) 1215–1220.
[4] F. Ahmad, M. Arad, N. Musi, H. He, C. Wolf, D. Branco, A.R. Perez-Atayde, D.
Stapleton, D. Bali, Y. Xing, R. Tian, L.J. Goodyear, C.I. Berul, J.S. Ingwall, C.E.
Seidman, J.G. Seidman, Increased alpha2 subunit-associated AMPK activity and
PRKAG2 cardiomyopathy, Circulation 112 (2005) 3140–3148.
[5] F. Bayrak, E. Komurcu-Bayrak, B. Mutlu, G. Kahveci, Y. Basaran, N. Erginel-
Unaltuna, Ventricular pre-excitation and cardiac hypertrophy mimicking hyper-
trophic cardiomyopathy in a Turkish family with a novel PRKAG2 mutation, Eur. J.
Heart Fail. 8 (2006) 712–715.
[6] R.T. Murphy, J. Mogensen, K. McGarry, A. Bahl, A. Evans, E. Osman, P. Syrris, G.
Gorman, M. Farrell, J.L. Holton, M.G. Hanna, S. Hughes, P.M. Elliott, C.A. Macrae,
W.J. McKenna, Adenosine monophosphate-activated protein kinase disease
mimicks hypertrophic cardiomyopathy and Wolff–Parkinson–White syndrome:
natural history, J. Am. Coll. Cardiol. 45 (2005) 922–930.
[7] M. Arad, J.G. Seidman, C.E. Seidman, Phenotypic diversity in hypertrophic
cardiomyopathy, Hum. Mol. Genet. 11 (2002) 2499–2506.
[8] S.K. Banerjee, R. Ramani, S. Saba, J. Rager, R. Tian, M.A. Mathier, F. Ahmad, A
PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and
does not protect against ischemia, Biochem. Biophys. Res. Commun. 360 (2007)
381–387.
[9] M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr., T.E. Cuddy, B.R. Davis,
E.M. Geltman, S. Goldman, G.C. Flaker, et al., Effect of captopril on mortality and
morbidity in patients with left ventricular dysfunction after myocardial infarction.
Results of the survival and ventricular enlargement trial. The SAVE Investigators,
N. Engl. J. Med. 327 (1992) 669–677.
[10] Y. Xing, N. Musi, N. Fujii, L. Zou, I. Luptak, M.F. Hirshman, L.J. Goodyear, R. Tian,
Glucose metabolism and energy homeostasis in mouse hearts overexpressing
dominant negative alpha2 subunit of AMP-activated protein kinase, J. Biol. Chem.
278 (2003) 28372–28377.
[11] F. Ahmad, S.K. Banerjee, M.L. Lage, X.N. Huang, S.H. Smith, S. Saba, J. Rager, D.A.
Conner, A.M. Janczewski, K. Tobita, J.P. Tinney, I.P. Moskowitz, A.R. Perez-Atayde,
B.B. Keller, M.A. Mathier, S.G. Shroff, C.E. Seidman, J.G. Seidman, The role of cardiac
troponin T quantity and function in cardiac development and dilated cardiomy-
opathy, PLoS ONE 3 (2008) e2642.
[12] T. Kubota, M. Miyagishima, C.S. Frye, S.M. Alber, G.S. Bounoutas, T. Kadokami, S.C.
Watkins, C.F. McTiernan, A.M. Feldman, Overexpression of tumor necrosis factor-
alpha activates both anti- and pro-apoptotic pathways in the myocardium, J. Mol.
Cell. Cardiol. 33 (2001) 1331–1344.
[13] S.K. Banerjee, K.R. McGafﬁn, N.M. Pastor-Soler, F. Ahmad, SGLT1 is a novel cardiac
glucose transporter that is perturbed in disease states, Cardiovasc. Res. 84 (2009)
111–118.
[14] H. Yoon, Y.T. Oh, J.Y. Lee, J.H. Choi, J.H. Lee, H.H. Baik, S.S. Kim, W. Choe, K.S. Yoon,
J. Ha, I. Kang, Activation of AMP-activated protein kinase by kainic acid mediates
brain-derived neurotrophic factor expression through a NF-kappaB dependent
mechanism in C6 glioma cells, Biochem. Biophys. Res. Commun. 371 (2008)
495–500.
[15] J.E. Jung, J. Lee, J. Ha, S.S. Kim, Y.H. Cho, H.H. Baik, I. Kang, 5-Aminoimidazole-4-
carboxamide-ribonucleoside enhances oxidative stress-induced apoptosis
through activation of nuclear factor-kappaB in mouse Neuro 2a neuroblastoma
cells, Neurosci. Lett. 354 (2004) 197–200.
[16] J.H. Han, Y.H. Ahn, K.Y. Choi, S.H. Hong, Involvement of AMP-activated protein
kinase and p38 mitogen-activated protein kinase in 8-Cl-cAMP-induced growth
inhibition, J. Cell. Physiol. 218 (2009) 104–112.
[17] C. Cao, S. Lu, R. Kivlin, B. Wallin, E. Card, A. Bagdasarian, T. Tamakloe, W.M. Chu,
K.L. Guan, Y. Wan, AMP-activated protein kinase contributes to UV- and H2O2-
induced apoptosis in human skin keratinocytes, J. Biol. Chem. 283 (2008)
28897–28908.[18] M. Jing, V.K. Cheruvu, F. Ismail-Beigi, Stimulation of glucose transport in response
to activation of distinct AMPK signaling pathways, Am. J. Physiol., Cell Physiol. 295
(2008) C1071–1082.
[19] M. Capano, M. Crompton, Bax translocates to mitochondria of heart cells during
simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated
protein kinases, Biochem. J. 395 (2006) 57–64.
[20] M.S. Kim, G. Kewalramani, P. Puthanveetil, V. Lee, U. Kumar, D. An, A. Abrahani, B.
Rodrigues, Acute diabetes moderates trafﬁcking of cardiac lipoprotein lipase
through p38 mitogen-activated protein kinase-dependent actin cytoskeleton
organization, Diabetes 57 (2008) 64–76.
[21] D. Nagata, A. Kiyosue, M. Takahashi, H. Satonaka, K. Tanaka, M. Sata, T. Nagano, R.
Nagai, Y. Hirata, A new constitutively active mutant of AMP-activated protein
kinase inhibits anoxia-induced apoptosis of vascular endothelial cell, Hypertens.
Res. 32 (2009) 133–139.
[22] D. Sag, D. Carling, R.D. Stout, J. Suttles, Adenosine 5′-monophosphate-activated
protein kinase promotes macrophage polarization to an anti-inﬂammatory
functional phenotype, J. Immunol. 181 (2008) 8633–8641.
[23] J.Y. Youn, T. Wang, H. Cai, An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling
cascade mediating VEGF-dependent endothelial nitric oxide production, Circ. Res.
104 (2009) 50–59.
[24] T.K. Sengupta, G.M. Leclerc, T.T. Hsieh-Kinser, G.J. Leclerc, I. Singh, J.C. Barredo,
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside
(AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for
targeted therapy, Mol. Cancer 6 (2007) 46.
[25] Y.C. Levine, G.K. Li, T. Michel, Agonist-modulated regulation of AMP-activated
protein kinase (AMPK) in endothelial cells. Evidence for an AMPK -N Rac1 -N
Akt -N endothelial nitric-oxide synthase pathway, J. Biol. Chem. 282 (2007)
20351–20364.
[26] J.S. Fisher, Potential role of the AMP-activated protein kinase in regulation of
insulin action, Cellscience 2 (2006) 68–81.
[27] W. Zhang, C. Xu, Calcium sensing receptor and heart diseases, Pathophysiology 16
(2009) 317–323.
[28] J.H. Boyd, S. Mathur, Y. Wang, R.M. Bateman, K.R. Walley, Toll-like receptor
stimulation in cardiomyocytes decreases contractility and initiates an NF-kappaB
dependent inﬂammatory response, Cardiovasc. Res. 72 (2006) 384–393.
[29] C.P. Dahl, L. Gullestad, B. Fevang, A.M. Holm, L. Landro, L.E. Vinge, A.E.
Fiane, W.J. Sandberg, K. Otterdal, S.S. Froland, J.K. Damas, B. Halvorsen, P.
Aukrust, E. Oie, A. Yndestad, Increased expression of LIGHT/TNFSF14 and its
receptors in experimental and clinical heart failure, Eur. J. Heart Fail. 10
(2008) 352–359.
[30] F. Wang, Y. Seta, G. Baumgarten, D.J. Engel, N. Sivasubramanian, D.L. Mann,
Functional signiﬁcance of hemodynamic overload-induced expression of
leukemia-inhibitory factor in the adult mammalian heart, Circulation 103
(2001) 1296–1302.
[31] A.M. Terrell, P.R. Crisostomo, G.M.Wairiuko, M.Wang, E.D. Morrell, D.R. Meldrum,
Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inﬂamma-
tion and hypertrophy in the heart, Shock 26 (2006) 226–234.
[32] J. Freeling, K. Wattier, C. LaCroix, Y.F. Li, Neostigmine and pilocarpine attenuated
tumour necrosis factor alpha expression and cardiac hypertrophy in the heart
with pressure overload, Exp. Physiol. 93 (2008) 75–82.
[33] P. Knuefermann, M. Schwederski, M. Velten, P. Krings, H. Ehrentraut, M. Rudiger,
O. Boehm, K. Fink, U. Dreiner, C. Grohe, A. Hoeft, G. Baumgarten, A. Koch, K.
Zacharowski, R. Meyer, Bacterial DNA induces myocardial inﬂammation and
reduces cardiomyocyte contractility: role of toll-like receptor 9, Cardiovasc. Res.
78 (2008) 26–35.
[34] H. Jin, W. Li, R. Yang, A. Ogasawara, H. Lu, N.F. Paoni, Inhibitory effects of
interferon-gamma on myocardial hypertrophy, Cytokine 31 (2005) 405–414.
[35] H.J. Han, Y.J. Jeon, Y.J. Lee, Involvement of NF-kappaB in high glucose-induced
alteration of alpha-methyl-D-glucopyranoside (alpha-MG) uptake in renal
proximal tubule cells, Cell. Physiol. Biochem. 13 (2003) 375–384.
[36] I. Luptak, M. Shen, H. He, M.F. Hirshman, N. Musi, L.J. Goodyear, J. Yan, H.
Wakimoto, H. Morita, M. Arad, C.E. Seidman, J.G. Seidman, J.S. Ingwall, J.A.
Balschi, R. Tian, Aberrant activation of AMP-activated protein kinase remodels
metabolic network in favor of cardiac glycogen storage, J. Clin. Invest. 117 (2007)
1432–1439.
[37] T.G. Canty Jr., E.M. Boyle Jr., A. Farr, E.N. Morgan, E.D. Verrier, T.H. Pohlman,
Oxidative stress induces NF-kappaB nuclear translocation without degradation of
IkappaBalpha, Circulation 100 (1999) II361–364.
[38] M. Wang, W.B. Zhang, B.Q. Zhou, G.S. Fu, Inﬂuence of various glucose levels on the
structure and function of cultured neonatal rats cardiomyocytes, Zhonghua Xin
Xue Guan Bing Za Zhi 36 (2008) 1027–1031.
[39] A. Sato, J.W. Funder, High glucose stimulates aldosterone-induced hypertrophy
via type I mineralocorticoid receptors in neonatal rat cardiomyocytes, Endocri-
nology 137 (1996) 4145–4153.
[40] N.H. Purcell, J.D. Molkentin, Is nuclear factor kappaB an attractive therapeutic
target for treating cardiac hypertrophy? Circulation 108 (2003) 638–640.
[41] V.P. van Empel, L.J. De Windt, Myocyte hypertrophy and apoptosis: a balancing
act, Cardiovasc. Res. 63 (2004) 487–499.
[42] L. Zelarayan, A. Renger, C. Noack, M.P. Zaﬁriou, C. Gehrke, R. van der Nagel, R.
Dietz, L. de Windt, M.W. Bergmann, NF-{kappa}B activation is required for
adaptive cardiac hypertrophy, Cardiovasc. Res. 84 (2009) 416–424.
[43] F.M. Heidrich, B.E. Ehrlich, Calcium, calpains, and cardiac hypertrophy: a new link,
Circ. Res. 104 (2009) e19–20.
[44] P.E. Light, C.H. Wallace, J.R. Dyck, Constitutively active adenosine monopho-
sphate-activated protein kinase regulates voltage-gated sodium channels in
ventricular myocytes, Circulation 107 (2003) 1962–1965.
